During replication of human inmunodeficiency virus type 1 (HIV-1), pro
teolytic cleavage of Gag and Gag-Pol precursor proteins into different
functional protein submits is catalyzed by the viral proteinase, and
this enzyme is the target of the antiviral proteinase inhibitor, Ro 31
-8959, We investigated in vitro which HIV mutants with reduced sensiti
vity to Ro 31-8959 emerged during proteinase inhibition treatment; fro
m three different HIV-1 strains, comparable progeny virus resistant to
proteinase inhibitor were found, whereas the same experimental protoc
ol detected no resistant HIV-2 mutants, Molecular analysis of the muta
tions underlying resistance revealed a multistep mechanism in which an
amino acid exchange at position 48 of the proteinase from glycine to
valine seemed to play an initial role, This amino acid exchange was co
mmon to all resistant isolates, and in all experiments preceded furthe
r exchanges at position 90 (leucine to methionine) and/or at position
54 (isoleucine to valine), For wild-type strains the 90% inhibitory co
ncentrations of Ro 31-8959 were close to 20 nM, whereas HIV-1 mutants
with all 3 amino acid exchanges had more than 50-fold increased 90% in
hibitory concentrations (above 1000 nM), The primary event (Gly-48 to
valine) occurs at the hinge of the flaps of the proteinase, thus hampe
ring entry of the inhibitor to the active center and suggesting steric
hindrance, Detailed knowledge of this stereotypic process could open
inhibitor design, thus preventing conceivable escape of resistant viru
s on proteinase inhibitor action.